A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007

Cancer

Volumn 107, Issue 2, 2006, Pages 319-327

  Worden, Francis P ^a,h   Moon, James ^b   Samlowski, Wolfram ^c   Clark, Joseph I ^d   Dakhil, Shaker R ^e   Williamson, Stephen ^f   Urba, Susan G ^a   Ensley, John ^g   Hussain, Maha H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^f UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

5 fluorouracil; Cisplatin; Dose response evaluation; Head and neck squamous cell carcinoma; Paclitaxel; Response Evaluation Criteria in Solid Tumors

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; DEXAMETHASONE; DIPHENHYDRAMINE; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERFERON; METHOTREXATE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHROCYTE CONCENTRATE; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECURRENT CANCER; RESPIRATORY TRACT INFECTION; SENSORY NEUROPATHY; SEPSIS; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; TREATMENT OUTCOME;

EID: 33745873717     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21994     Document Type: Article

References (33)

1. Hussain M, Benedetti J, Smith RE, et al. Evaluation of 96 hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. Cancer. 1995;76:1233-1237.
2. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245-1251.
3. Gibson M, Yi L, Murphy B, et al. Phase III evaluation of cisplatin and 5-fluorouracil versus cisplatin and paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562-3567.
4. Forastiere AA, Shank D, Neuberg D, et al. Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer. 1998;82:2270-2274.
5. Parker RJ, Dabholkar MD, Lee KB, et al. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst. 1993;15:83-88.
6. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a Phase I and pharmacologic study. J Clin Oncol. 1991;9:1692-1703.
7. Hussain M, Gadgeel S, Kucuk O, et al. Paclitaxel, cisplatin, 5-fluorouracil in patients with advanced/recurrent squamous cell carcinoma of the head and neck. Cancer. 1999;86:2364-2369.
8. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
9. National Cancer Institute. Investigator's handbook: a manual for participants in clinical trials of investigational agents sponsored by DCTD, NCI. Bethesda: National Cancer Institute, 1993.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
11. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer. Eastern Cooperative Oncology Group Study E1393. J Clin Oncol. 2001;19:1088-1095.
12. Basaran M, Bavbek SE, Gullu I, et al. A Phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J Chemother. 2002;14:207-213.
13. Thodtmann F, Theiss F, Kemmerich M, et al. Clinical Phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 1988;9:335-337.
14. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:1325-1330.
15. Benasso M, Numico G, Rosso R, et al. Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose finding study. Semin Oncol. 1997;24:S19-46-S19-50.
16. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a Phase II feasibility study. Am J Clin Oncol. 2000;23:128-131.
17. Recondo G, Armand JP, Tellez-Bernal E, et al. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope. 1991;101:494-501.
18. Schornagel JH, Verweij J, de Mulder PH, et al. Randomized Phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol. 1995;13:1649-1655.
19. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86:265-272.
20. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer. 2000;83:1594-1598.
21. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-950.
22. Pignon JP, Syz N, Posner M, et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs. 2004;15:331-340.
23. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin, plus 5-fluorouracil to paclitaxel, cisplatin, and 5-flurouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-3645.
24. Vermorken JB, Remenar E, van Herpen J, et al. Standard cisplatin/infusional 5-fluorouracil versus docetaxel plus cisplatin/infusional 5-fluoruracil as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck: a Phase III trial of the EORTC Head and Neck Cancer Group (EORTC 24971). Proc Am Soc Clin Oncol. 2004;5508:490. Abstract.
25. Pivot X, Niyikiza C, Poissonnet G, et al. Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials. Oncology. 2001;61:197-204.
26. Argiris A, Li Y, Murphy BA, et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol. 2004;22:262-268.
27. Hitt R, Paz-Ares L, Brandariz A, et al. Induction chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a Phase II trial. Ann Oncol. 2002;13:1665-1673.
28. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicenter randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161-1171.
29. du Bois A, Luck HJ, Meier W, et al. A randomized trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-1329.
30. Alberts DS. Carboplatin versus cisplatin in ovarian cancer. Semin Oncol. 1995;22:88-90.
31. Takimoto C, Rowinsky E. Dose-intense paclitaxel: deja vu all over again? J Clin Oncol. 2003;21:2810-2814.
32. Hitt R, Jimeno A, Millan JM, et al. Phase II trial of dose-dense paclitaxel, cisplatin, and 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Anticancer Drugs. 2004;15:331-340.
33. Fountzilas G, Athanassiadis A, Samantas E, et al. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a Phase II study. Semin Oncol. 1997;24(Suppl 2): S2-65-S2-67.